InxMed Announces Clinical Collaboration to Evaluate IN10018 in Combination with Cobimetinib
October 12, 2019
Shanghai, China – InxMed (Shanghai) Co., Ltd., (“InxMed” or “Company”) today announced that the company has entered into a clinical collaboration with Roche (F. Hoffmann-La Roche Ltd.,) to evaluate IN10018, a proprietary focal adhesion kinase (FAK) inhibitor in combination with Roche’s Cobimetinib, an inhibitor of mitogen-activated protein kinase (MEK). This trial was designed to evaluate the safety, tolerability, and antitumor activity of IN10018 of the combination therapy in patients with melanoma. InxMed will be the study sponsor and Roche will provide InxMed with Cobimetinibto use in the clinical study.
Dr. Richard Carvajal, Director of Experimental Therapeutics and Director of Melanoma Service in Columbia University Medical Center, commented: “We have been working on the development of new therapies for melanoma and other cancer patients. With solid disease biology, the early research data of IN10018 in combination with MEK inhibitor and Cobimetinib combination is very exciting. We hope that this combination therapy can provide a better treatment option for melanoma patients.”
“Roche chose InxMed as a partner to develop Cobimetinib, not only due to the great potential of IN10018, but also showing the recognition of our clinical development team and capability.”, Dr. Zaiqi Wang, InxMed’s Chairman and CEO, said: “We are looking forward to a new breakthrough in the treatment of melanoma. This cooperation marks an important milestone towards globalization of our company, a biotech company positioned as "China innovation, global impact" in the era 2.0 of new drug R&D.”
IN10018, formerly known as BI853520, is a potent and selective ATP-competitive focal adhesion kinase (FAK) small molecule inhibitor under clinical development stage in both the United States and China. InxMed owns the exclusive global rights for development and commercialization. Early clinical data of IN10018 has demonstrated a favorable safety profile and promising efficacy signals against a number of tumor types. Emerging science also showed that FAKi like IN10018 potentially overcomes fibrotic barrier and immune tolerance, boosting multi-modalities including targeted therapy, chemotherapy, immune-therapy and radiation therapy.
InxMed is a clinical-stage biotech company focusing on developing “Best-in-Disease Combination” medicines to bring novel treatment option for patients. Our innovations are inspired by patients and driven by in-depth understanding of disease biology and pharmacology. InxMed is committed to building a translational platform equipped with global-level top-notch know how and efficient execution capabilities. Established in the end of 2018, InxMed has raised tens of millions of US dollars in series A round financing, established an integrated high caliber research and clinical development team across Shanghai, Beijing, United States, Canada and Australia. We have built a highly differentiated pipeline, and established licensing or co-development partnership with various multinational pharmaceutical companies.
For more information, please visit our website: www.inxmed.com.